Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Nov;80(16):1739-1744.
doi: 10.1007/s40265-020-01414-9.

Oliceridine: First Approval

Anthony Markham  1
Affiliations
Review

Oliceridine: First Approval

Anthony Markham. Drugs. 2020 Nov.

Erratum in

Abstract

Oliceridine (Olinvyk™, Trevena, Inc.) is a novel μ opioid agonist that was recently approved in the USA for use in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Unlike opioid agonists currently in use, the interaction of oliceridine with the opioid receptor is selective to the G protein pathway, with low potency for β-arrestin recruitment, which may lead to fewer opioid-related adverse events. This article summarizes the milestones in the development of oliceridine leading to this first approval.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Trevena Inc. Trevena announces FDA has set PDUFA date of August 7, 2020 for oliceridine [media release]. 5 Mar 2020. https://www.trevena.com/ .
    1. DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344(3):708–17. - DOI
    1. Trevena Inc. OLINVYKTM (oliceridine) injection, for intravenous use, [controlled substance schedule pending]: US prescribing information. 2020. https://olinvyk.com/ . Accessed 12 Aug 2020.
    1. US Food & Drug Administration. FDA approves new opioid for intravenous use in hospitals, other controlled clinical settings [media release]. 7 Aug 2020. https://www.fda.gov/ .
    1. Bergese SD, Brzezinski M, Hammer GB, et al. ATHENA: a phase 3, open-label study of the safety and effectiveness of oliceridine (TRV130), a G-protein selective agonist at the µ-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy. J Pain Res. 2019;12:3113–266. - DOI

MeSH terms

Substances

LinkOut - more resources